Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD GlobeNewswire - Tue Dec 2, 6:30AM CST

CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.62 (-1.82%)
Zevra Therapeutics, Inc. Announces CFO Transition GlobeNewswire - Thu Nov 20, 3:05PM CST

CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.62 (-1.82%)
Zevra Therapeutics: Q3 Earnings Snapshot AP - Wed Nov 5, 3:48PM CST

Zevra Therapeutics: Q3 Earnings Snapshot

ZVRA : 8.62 (-1.82%)
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update GlobeNewswire - Wed Nov 5, 3:05PM CST

2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million , driven by MIPLYFFA ® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5,...

ZVRA : 8.62 (-1.82%)
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference GlobeNewswire - Wed Oct 29, 6:30AM CDT

CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.62 (-1.82%)
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call GlobeNewswire - Mon Oct 27, 6:30AM CDT

CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.62 (-1.82%)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Oct 6, 4:51PM CDT

CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.62 (-1.82%)
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium... GlobeNewswire - Thu Sep 18, 6:30AM CDT

MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC...

ZVRA : 8.62 (-1.82%)
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) GlobeNewswire - Thu Sep 4, 6:30AM CDT

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award...

ZVRA : 8.62 (-1.82%)
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) GlobeNewswire - Thu Aug 28, 6:30AM CDT

CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 8.62 (-1.82%)

Barchart Exclusives

MicroStrategy Is Still Betting on a Bitcoin Comeback to Lift Beaten-Down MSTR Stock Barchart - 5 minutes ago
MicroStrategy stock is down over 60% from its all-time high amid falling Bitcoin prices over the last two months. Is MSTR stock ripe for a comeback? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot